Multiparametric flow cytometry highlights B7-H3 as a novel diagnostic/therapeutic target in GD2neg/low neuroblastoma variants.

Alessandra DonderoMartina MoriniDavide CangelosiKatia MazzoccoMartina SerraGrazia Maria SpaggiariGianluca RottaAnnalisa TondoFranco LocatelliAurora CastellanoFrancesca ScuderiAngela Rita SementaAlessandra EvaMassimo ConteAlberto GaraventaCristina BottinoRoberta Castriconi

Published in: Journal for immunotherapy of cancer (2021)

Our study validates a sensitive MFC analysis providing information on GD2 and B7-H3 surface expression and allowing fast, specific and sensitive evaluation of BM tumor burden. With other routinely used diagnostic and prognostic tools, MFC can improve diagnosis, prognosis, orienting novel personalized treatments in patients with GD2low/neg NB, who might benefit from innovative therapies combining B7-H3 targeting.

Keyphrases

flow cytometry
poor prognosis
copy number
healthcare
cancer therapy
risk factors
gene expression
dna methylation
binding protein